Helus
Business Services · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.helus.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Helus
Helus Inc is a company that operates in the Research & Development industry. It employs 50to99 people and has 10Mto25M of revenue. The company is headquartered in the United States.Explore more
Helus Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Helus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Helus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Helus has new funding data
Click to see if Helus had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Helus
Check if Helus has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Helus recently announced quarterly report
Product Launch: Get notified when Helus launches new products
Check out if Helus is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Helus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Helus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Helus.
Helus Tech Stack
A closer look at the technologies used by Helus
See more technologies
Most Recent Scoops
Project
Helus has structured its second phase III with three arms placebo, 8 mg, and 16 mg with the 8 mg arm included to address the FDA's preference for the lowest effective dose, potentially providing physicians with a range of dosing options on the final label.
Pharmaceuticals, Clinical Operations
Project
Helus has a phase III program in major depressive disorder (MDD) using a deuterated psilocin molecule, with a top-line phase III readout expected in Q4 of this year. Phase II results demonstrated remission rates exceeding 71% at 12 months and over 13 points of separation from MADRS at the primary endpoint, reaching nearly 23 points of separation over 12 months.
Pharmaceuticals, Clinical Operations
Project
holds more than 350 patent filings with over 100 granted, providing patent protection for its compounds extending to at least 2041, which the company states supports commercialization well beyond the seven-year marketing exclusivity available to some peers.
Intellectual Property, Legal Affairs
Project
Helus has reported that no suicidal ideation was observed in its phase II CYB003 trial, with the drug described as well-tolerated and any adverse events, such as transient blood pressure increases, subsiding following treatment.
Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Helus News & Media
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
Issued on behalf of Helus Pharma™ Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:...Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunityHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 -Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share for aggregate
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Helus
Sign Up For FreeTo access detailed company insights
Helus Inc is a company that operates in the Research & Development industry. It employs 50to99 people and has 10Mto25M of revenue. The company is headquartered in the United States.... Read More
